The Partnership for Research on Ebola Virus in Liberia (PREVAIL), a US-Liberia joint clinical research partnership, recently announced the opening of PREVAIL IV, a trial for male Ebola survivors with persistent Ebola virus RNA in their semen (http://bit.ly/29OtRa9). The trial is sponsored by the National Institute of Allergy and Infectious Diseases in partnership with the Ministry of Health of Liberia and Gilead Sciences. The six-month randomized, double-blind study will enroll 60 to 120 male Ebola survivors whose semen tested positive for Ebola virus RNA.
Slomski A. Trial Launched to Eradicate Ebola From Semen. JAMA. 2016;316(8):809. doi:10.1001/jama.2016.11464